Erythromycin DDI Study with Verducatib

Phase 1, open-label, single-arm trial of verducatib in bronchiectasis, sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of BI 1291583 in plasma at steady state over a uniform dosing interval τ up to 72 days and Maximum measured concentration of BI 1291583 in plasma at steady state over a uniform dosing interval τ up to 72 days. Started Apr 2025; status: completed.